{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:04:44Z","timestamp":1793376284493,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","award":["NL8921"],"award-info":[{"award-number":["NL8921"]}],"id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016238","name":"Ministerie van Economische Zaken en Klimaat","doi-asserted-by":"publisher","award":["PPP-2019_007"],"award-info":[{"award-number":["PPP-2019_007"]}],"id":[{"id":"10.13039\/501100016238","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ebiom.2023.104883","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:10:43Z","timestamp":1700698243000},"page":"104883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["High serum C-X-C motif chemokine ligand 10 (CXCL10) levels may be associated with new onset interstitial lung disease in patients with systemic sclerosis: evidence from observational, clinical, transcriptomic and in\u00a0vitro studies"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5406-7604","authenticated-orcid":false,"given":"Yehya","family":"Al-Adwi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella Maria","family":"Atzeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berber","family":"Doornbos-van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel John","family":"van der Leij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita Delphine Maiko","family":"Varkevisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart-Jan","family":"Kroesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alja","family":"Stel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Timens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiaan Tji","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6670-1577","authenticated-orcid":false,"given":"Harry","family":"van Goor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Westra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douwe Johannes","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ebiom.2023.104883_bib1","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/1744666X.2019.1614915","article-title":"Pathophysiology of systemic sclerosis: current understanding and new insights","volume":"15","author":"Cutolo","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"137","key":"10.1016\/j.ebiom.2023.104883_bib2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1183\/16000617.00002915","article-title":"Interstitial lung disease in systemic sclerosis: where do we stand?","volume":"24","author":"Cappelli","year":"2015","journal-title":"Eur Respir Rev"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104883_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/2397198320915042","article-title":"Update on morbidity and mortality in systemic sclerosis\u2013related interstitial lung disease","volume":"6","author":"Volkmann","year":"2020","journal-title":"J\u00a0Scleroderma Relat Disord"},{"key":"10.1016\/j.ebiom.2023.104883_bib4","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02026-2019","article-title":"Predictors of progression in systemic sclerosis patients with interstitial lung disease","volume":"55","author":"Distler","year":"2020","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.ebiom.2023.104883_bib5","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3899\/jrheum.170518","article-title":"KL-6 but not CCL-18 is a predictor of early progression in systemic sclerosis-related interstitial lung disease","volume":"45","author":"Salazar","year":"2018","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104883_bib6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.ebiom.2023.104883_bib7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104883_bib8","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12967-021-02822-5","article-title":"Chemokines and their receptors: predictors of the therapeutic potential of mesenchymal stromal cells","volume":"19","author":"Cuesta-Gomez","year":"2021","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.ebiom.2023.104883_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2013.00266","article-title":"The role of type 1 interferon in systemic sclerosis","volume":"4","author":"Wu","year":"2013","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.ebiom.2023.104883_bib10","first-page":"1662","article-title":"Type I interferon\u2013mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy","volume":"56","author":"Psarras","year":"2017","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.ebiom.2023.104883_bib11","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/ard.2011.150326","article-title":"Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway","volume":"70","author":"Higgs","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104883_bib12","doi-asserted-by":"crossref","first-page":"R74","DOI":"10.1186\/ar616","article-title":"A\u00a0novel mechanism for the regulation of IFN-\u03b3 inducible protein-10 expression in rheumatoid arthritis","volume":"5","author":"Hanaoka","year":"2003","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.ebiom.2023.104883_bib13","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1210\/jcem.86.10.7953","article-title":"Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and mig and attract CXCR3+ lymphocytes","volume":"86","author":"Garc\u00cda-L\u00f3pez","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ebiom.2023.104883_bib14","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00125-002-0879-5","article-title":"Serum concentrations of the interferon-\u03b3-inducible chemokine IP-10\/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease","volume":"45","author":"Nicoletti","year":"2002","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104883_bib15","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","article-title":"Chemokine (C\u2013X\u2013C motif) ligand (CXCL)10 in autoimmune\u00a0diseases","volume":"13","author":"Antonelli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ebiom.2023.104883_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2018.00271","article-title":"The role of CXCR3 and its chemokine ligands in skin disease and cancer","volume":"5","author":"Kuo","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.ebiom.2023.104883_bib17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cyto.2017.04.010","article-title":"Pro-inflammatory effects of the Th1 chemokine CXCL10 in acquired aplastic anaemia","volume":"94","author":"Li","year":"2017","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104883_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/icb.2010.158","article-title":"CXCR3 ligands: redundant, collaborative and antagonistic functions","volume":"89","author":"Groom","year":"2011","journal-title":"Immunol Cell Biol"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104883_bib19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jdermsci.2004.03.001","article-title":"Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis","volume":"35","author":"Fujii","year":"2004","journal-title":"J\u00a0Dermatol Sci"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104883_bib20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/rheumatology\/kem313","article-title":"CXCL10 (\u03b1) and CCL2 (\u03b2) chemokines in systemic sclerosis\u2014a longitudinal study","volume":"47","author":"Antonelli","year":"2008","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.ebiom.2023.104883_bib21","first-page":"939","article-title":"Augmentation de CXCL10 dans le s\u00e9rum au cours de la pneumopathie interstitielle de la scl\u00e9rodermie syst\u00e9mique","volume":"1496","author":"Tiev","year":"2009","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.ebiom.2023.104883_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1189257","article-title":"The soluble receptor for advanced glycation end products is potentially predictive of pulmonary arterial hypertension in systemic sclerosis","volume":"14","author":"Atzeni","year":"2023","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.ebiom.2023.104883_bib23","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American College of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104883_bib24","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12931-022-02046-1","article-title":"Th1 cytokines synergize to change gene expression and promote corticosteroid insensitivity in pediatric airway smooth muscle","volume":"23","author":"Jackson","year":"2022","journal-title":"Respir Res"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104883_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/antiox12040794","article-title":"Release of high-mobility group box-1 after a raynaud's attack leads to fibroblast activation and interferon-\u03b3 induced protein-10 production: role in systemic sclerosis pathogenesis","volume":"12","author":"Al-Adwi","year":"2023","journal-title":"Antioxidants"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104883_bib26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/art.1780400422","article-title":"Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis","volume":"40","author":"Bolster","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.ebiom.2023.104883_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241719","article-title":"CXCL9, CXCL10, and CXCL11; biomarkers of pulmonary inflammation associated with autoimmunity in patients with collagen vascular diseases\u2013associated interstitial lung disease and interstitial pneumonia with autoimmune features","volume":"15","author":"Kameda","year":"2020","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ebiom.2023.104883_bib28","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1002\/art.40243","article-title":"Earliest phase of systemic sclerosis typified by increased levels of inflammatory proteins in the serum","volume":"69","author":"Cossu","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.ebiom.2023.104883_bib29","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/rheumatology\/kez230","article-title":"Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature","volume":"58","author":"Bonhomme","year":"2019","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.ebiom.2023.104883_bib30","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1136\/annrheumdis-2018-213257","article-title":"Association of circulating CXCL10 and CXCL11 with systemic sclerosis","volume":"77","author":"Crescioli","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104883_bib31","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13075-018-1545-8","article-title":"Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis","volume":"20","author":"Weigold","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104883_bib32","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1164\/rccm.200502-244OC","article-title":"Role of the chemokine receptors CXCR3 and CCR4 in human pulmonary fibrosis","volume":"173","author":"Pignatti","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104883_bib33","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/path.2277","article-title":"Cellular and molecular mechanisms of fibrosis","volume":"214","author":"Wynn","year":"2008","journal-title":"J\u00a0Pathol"},{"issue":"6","key":"10.1016\/j.ebiom.2023.104883_bib34","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1183\/09031936.01.00074101","article-title":"Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF","volume":"17","author":"Pan","year":"2001","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104883_bib35","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3899\/jrheum.120725","article-title":"Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis","volume":"40","author":"De Lauretis","year":"2013","journal-title":"J\u00a0Rheumatol"},{"issue":"7","key":"10.1016\/j.ebiom.2023.104883_bib36","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/annrheumdis-2011-200955","article-title":"Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis","volume":"71","author":"Khan","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ebiom.2023.104883_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01093","article-title":"Coordination of immune-stroma crosstalk by IL-6 family cytokines","volume":"10","author":"West","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2023.104883_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01970","article-title":"Overview of the mechanisms that may contribute to the non-redundant activities of interferon-inducible CXC chemokine receptor 3 ligands","volume":"8","author":"Metzemaekers","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104883_bib39","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12974-016-0675-7","article-title":"Interleukin-6, MCP-1, IP-10, and MIG are sequentially expressed in\u00a0cerebrospinal fluid after subarachnoid hemorrhage","volume":"13","author":"Niwa","year":"2016","journal-title":"J\u00a0Neuroinflammation"},{"issue":"12","key":"10.1016\/j.ebiom.2023.104883_bib40","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/s41590-019-0466-2","article-title":"Interferon target-gene expression and epigenomic signatures in health and disease","volume":"20","author":"Barrat","year":"2019","journal-title":"Nat Immunol"},{"issue":"7","key":"10.1016\/j.ebiom.2023.104883_bib41","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/eji.202048922","article-title":"JAK inhibitors: ten years after","volume":"51","author":"Spinelli","year":"2021","journal-title":"Eur J Immunol"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104883_bib42","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2217\/imt-2020-0270","article-title":"The rationale for targeting the JAK\/STAT pathway in scleroderma-associated interstitial lung disease","volume":"13","author":"Talotta","year":"2020","journal-title":"Immunotherapy"},{"issue":"17","key":"10.1016\/j.ebiom.2023.104883_bib43","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159566","article-title":"Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial","volume":"7","author":"Khanna","year":"2022","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.ebiom.2023.104883_bib44","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104883_bib45","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s10753-020-01322-w","article-title":"Inhibition of JAK-STAT signaling by baricitinib reduces interferon-\u03b3-induced CXCL10 production in human salivary gland ductal cells","volume":"44","author":"Aota","year":"2021","journal-title":"Inflammation"},{"key":"10.1016\/j.ebiom.2023.104883_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114103","article-title":"Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in\u00a0vitro and in\u00a0vivo: perspectives for scleroderma-associated interstitial lung disease","volume":"178","author":"Lescoat","year":"2020","journal-title":"Biochem Pharmacol"},{"issue":"17","key":"10.1016\/j.ebiom.2023.104883_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231710150","article-title":"The prostacyclin analogue iloprost modulates CXCL10 in systemic sclerosis","volume":"23","author":"Colasanti","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.ebiom.2023.104883_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22062894","article-title":"Muscle damage in systemic sclerosis and CXCL10: the potential therapeutic role of PDE5 inhibition","volume":"22","author":"Corinaldesi","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104883_bib49","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/rheumatology\/keac410","article-title":"Macrophages as determinants and regulators of\u00a0fibrosis in systemic sclerosis","volume":"62","author":"Al-Adwi","year":"2023","journal-title":"Rheumatology"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396423004498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396423004498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T14:42:33Z","timestamp":1737384153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396423004498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":49,"alternative-id":["S2352396423004498"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2023.104883","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High serum C-X-C motif chemokine ligand 10 (CXCL10) levels may be associated with new onset interstitial lung disease in patients with systemic sclerosis: evidence from observational, clinical, transcriptomic and in\u00a0vitro studies","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2023.104883","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104883"}}